Early Stage Drug Discovery in Disease Segments

1. Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies

2. Oncology is the Key Therapeutic Segment of the Early Stage Drug Pipeline Early stage drug development includes drugs under development in the discovery and preclinical stages of development. These studies are conducted in order to assess the safety and efficacy of the drug. This stage of development plays a key role in drug development as it determines potential molecules to be further processed for development by different companies. Increased strategies like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are persuading companies to implement safety scrutiny measures at early stages of development. The majority of the molecules in the early stages of development are being developed for cancer indications. Molecules under development for breast cancer account for 23% of the total early stage development molecules under development for cancer. This is followed by prostate cancer, accounting for 20%, followed by colon cancer (15%). For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Early-Stage-Drug-Discovery-in-Disease-Segments-Innovation-Focuses-on-Stem-Cell-Therapies-and-Gene-Therapies&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

3. Other than Oncology, other therapeutic areas with high activity in Research and Development (R&D) in early development phases include Central Nervous System (CNS) disorders, immunological disorders, and metabolic disorders. CNS disorders accounted for 14% of early stage drugs under development, followed by immunological disorders (13%) and metabolic disorders (10%). Compared to other therapeutic areas, there is less R&D activity in the metabolic disorders (9%) and infectious disease (9%) segments. Breast Cancer Therapeutics Leads the Early Stage Drug Developmental Pipeline; Immunotherapy accounts for 33% of the Drug Classes Under Development The breast cancer early stage pipeline consists of 141 molecules, with 22 molecules in the discovery phase and 119 molecules in the preclinical phase. These molecules are in development for the treatment of patients suffering with breast cancer. The discovery phase of the breast cancer pipeline consists of 16% of the molecules and the preclinical phase consists of 84% of the pipeline. The early stage breast cancer therapeutics pipeline has been supplemented by novel therapeutic molecules. Immunotherapy, with 47 molecules, contributes 33% of the pipeline. Protein receptor targetors contribute 16%. Enzyme inhibitors contribute 12% of the pipeline. Vaccines contribute 8% of the pipeline. Gene

4. therapy contributes 5% of the pipeline. Apoptosis targetors contribute to 3%. Chemotherapy, angiogenic antagonists, stem cell therapy and hormones with two molecules each contribute 1%. Combination therapy, with three molecules, contributes 2%. Cellular motility inhibitors, synthetic picolinic ester-substituted retinoids, microtubule inhibitors with one molecule each contribute to 1% each. Few drugs with the mechanisms of action apart from these major classes contribute to 13% of the pipeline. Key Players in the Early Stage Drug Development Pipeline are Hanall Pharmaceutical, Patrys and F. Hoffman La Roche In early stage drug development, as in, drugs in the discovery and preclinical phases of development, the key players were identified to be Hanall Pharmaceutical Co. Ltd, Patrys Limited, F. Hoffman La Roche, Mirna Therapeutics and Aphios Corporation. These key players showed immense activity in R&D in the early stages of drug development in different therapeutic areas like CNS, cardiovascular diseases, oncology, infection, immunological disorders and metabolic disorders. Hanall Pharmaceuticals has 39 molecules in discovery as well as preclinical stage Parkinson’s disease, diabetes, Alzheimer’s disease, hepatitis, allergy and hypertension. Patrys Limited has 19 molecules in development in the discovery and preclinical stages of development in different therapeutic segments like ovarian cancer, lung cancer

5. and colon cancer. Roche has 17 molecules in development in the discovery and preclinical stages of development in different therapeutic segments like prostate cancer, lung cancer, melanoma, breast cancer, colon cancer, schizophrenia, obesity and Human Immunodeficiency Virus (HIV) that causes Acquired Immunodeficiency Syndrome (AIDS). GBI Research, the leading business intelligence provider, has released its latest research, “Early Stage Drug Discovery in Disease Segments – Innovation Focuses on Stem Cell Therapies and Gene Therapies”. It provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease and Oncology therapeutic markets. The report analyzes the early stage drug development that includes drugs under development in the discovery and preclinical stages of development for the above mentioned indications in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and the annual cost of therapy are forecast until 2017 for the key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the Mergers and Acquisitions (M&A) and licensing agreements that shape the global market.

6. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Early-Stage-Drug-Discovery-in-Disease-Segments-Innovation-Focuses-on-Stem-Cell-Therapies-and-Gene-Therapies&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Visit our report store: http://www.gbiresearch.com For more details contact: pressreleases@gbiresearch.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782